New share issues provide Bluefish Pharmaceuticals with SEK 79 million

The Swedish generic pharmaceuticals company Bluefish has successfully completed three new share issues, which in total provides the company with SEK 79 million. By securing liquidity and improving the financial strength, the company creates the conditions necessary for continued stable growth and opportunities for gradually extending the range of niche products within more narrow disease areas and for regional treatment principles.

Through the new share issues, the number of shares in Bluefish has increased by 13 187 667. The subscription price was SEK 6.0 for each new share. Following the new share issues, the total number of shares in Bluefish amounts to 58 803 187 and the share capital amounts to SEK 11 760 637.

For more information contact,

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in 19 European markets and has a technology center in Bangalore, India. The product portfolio consists of a total of 83 products and is growing.

www.bluefishpharma.com